IMATINIB 800MG DAILY INDUCES DEEPER MOLECULAR RESPONSES THAN IMATINIB 400MG DAILY: RESULTS OF SWOG S0325, AN INTERGROUP RANDOMIZED PHASE II TRIAL IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKAEMIA

The standard dose of imatinib for newly diagnosed patients with chronic phase chronic myeloid leukemia (CP-CML) is 400mg daily (IM400), but the optimal dose is unknown. This randomized phase II study compared the rates of molecular, haematologic and cytogenetic response to IM400 vs. imatinib 400mg t...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Deininger, Michael W., Kopecky, Kenneth J., Radich, Jerald P., Kamel-Reid, Suzanne, Stock, Wendy, Paietta, Elisabeth, Emanuel, Peter D., Tallman, Martin, Wadleigh, Martha, Larson, Richard A., Lipton, Jeffrey H., Slovak, Marilyn L., Appelbaum, Frederick R., Druker, Brian J.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4127316/
https://ncbi.nlm.nih.gov/pubmed/24383843
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.12618
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky